Hematopoietic cell transplantation and cell therapy activity landscape survey in the Kingdom of Saudi Arabia; a report from the Saudi Society of Blood and Marrow Transplantation (SSBMT) - Report - MDSpire
Advertisement
Hematopoietic cell transplantation and cell therapy activity landscape survey in the Kingdom of Saudi Arabia; a report from the Saudi Society of Blood and Marrow Transplantation (SSBMT)
By
On behalf of Saudi Society of Blood & Marrow Transplantation (SSBMT)
Survey of Hematopoietic Cell Transplantation Practices in Saudi Arabia: 2018–2022 Insights
Overview
This survey reports on hematopoietic cell transplantation (HCT) activity in Saudi Arabia from 2018 to 2022, highlighting a significant increase in transplant numbers and expansion of HCT centers. The majority of transplants were allogeneic, with pediatric patients receiving more allogeneic HCTs, and most donors being fully HLA-matched.
Background
Hematopoietic cell transplantation is a curative treatment for various malignant and non-malignant hematologic disorders. Saudi Arabia has seen a rising incidence of hematologic cancers and sickle cell disease, increasing the demand for HCT. Since the first transplant in 1984, the number of HCT centers and procedures has expanded substantially. This survey aimed to capture recent trends in HCT activity, infrastructure, and practices across the Kingdom.
Data Highlights
Parameter
Value
Total first HCTs since 1984
15,031
Allogeneic HCTs
10,489 (70%)
Autologous HCTs
4,542 (30%)
Adult HCTs
10,232 (68%)
Pediatric HCTs
4,799 (32%)
HCTs performed 2018–2022
5,164
HCT centers
8 total (5 Central, 2 Western, 1 Eastern)
Bed capacity by region
Central: 77, Western: 41, Eastern: 18
Population to bed ratio (per million)
Central: 7.21, Western: 4.03, Eastern: 3.51
Donor type for allogeneic HCT
85% full HLA match
Transplant rate per 10 million (2016)
157.06
Key Findings
Since 1984, 15,031 first HCTs were performed in Saudi Arabia, with 70% being allogeneic and 30% autologous.
Between 2018 and 2022, 5,164 HCTs were conducted, showing a swift increase in transplant activity.
The Central region accounts for the majority of HCT activity, with 5 centers and the highest bed capacity.
Pediatric patients received a higher proportion of allogeneic transplants compared to adults.
Most allogeneic transplants used fully HLA-matched donors (85%).
Three centers have achieved international accreditation (FACT or JACIE), with others pursuing accreditation.
Clinical Implications
The expanding HCT infrastructure and increasing transplant numbers in Saudi Arabia reflect improved access to curative therapies for hematologic diseases. The predominance of fully HLA-matched donors and pediatric allogeneic transplants underscores the importance of donor registries and pediatric transplant programs. Continued accreditation efforts and registry reporting will enhance quality and outcomes.
Conclusion
Hematopoietic cell transplantation in Saudi Arabia has grown substantially over recent years, with increasing numbers of procedures and centers, particularly in the Central region. This survey provides valuable insights into current practices and highlights areas for ongoing development to meet rising clinical demands.
References
Saudi Cancer Registry Report -- Cancer Incidence in Saudi Arabia
European Society for Blood and Marrow Transplantation (EBMT) Data
Saudi Society of Blood and Marrow Transplantation (SSBMT) Survey 2022
